Sharma Anu, Greene Dina N, Chambliss Allison B, Farnsworth Christopher W, French Deborah, Herman Daniel S, Kavsak Peter A, Merrill Anna E, Margaret Lo Sheng-Ying, Lyon Martha E, Winston-McPherson Gabrielle, Pearson Lauren N, SoRelle Jeffrey A, Waring Avantika C, Schmidt Robert L
Division of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, United States.
Kaiser Permanente Washington, Renton, WA, United States.
Clin Chim Acta. 2021 Aug;519:148-152. doi: 10.1016/j.cca.2021.04.018. Epub 2021 Apr 28.
The coronavirus disease 2019 (COVID-19) pandemic caused a halt to in-person ambulatory care. We evaluated how the reduction in access to care affected HbA1c testing and patient HbA1c levels.
HbA1c data from 11 institutions were extracted to compare testing volume and the percentage of abnormal results between a pre-pandemic period (January-June 2019, period 1) and a portion of the COVID-19 pandemic period (Jan-June 2020, period 2). HbA1c results greater than 6.4% were categorized as abnormal.
HbA1C testing volumes decreased in March, April and May by 23, 61 and 40% relative to the corresponding months in 2019. The percentage of abnormal results increased in April, May and June (25, 23, 9%). On average, we found that the frequency of abnormal results increased by 0.31% for every 1% decrease in testing volume (p < 0.0005).
HbA1c testing volume for outpatients decreased by up to 70% during the early months of the pandemic. The decrease in testing was associated with an increase in abnormal HbA1c results.
2019年冠状病毒病(COVID-19)大流行导致门诊医疗服务暂停。我们评估了医疗服务可及性的降低对糖化血红蛋白(HbA1c)检测及患者HbA1c水平的影响。
提取了11家机构的HbA1c数据,以比较大流行前时期(2019年1月至6月,时期1)和COVID-19大流行时期的一部分(2020年1月至6月,时期2)之间的检测量和异常结果百分比。HbA1c结果大于6.4%被归类为异常。
与2019年相应月份相比,3月、4月和5月的HbA1c检测量分别下降了23%、61%和40%。4月、5月和6月异常结果的百分比有所增加(分别为25%、23%、9%)。我们发现,平均而言,检测量每下降1%,异常结果的频率就增加0.31%(p<0.0005)。
在大流行的最初几个月,门诊患者的HbA1c检测量下降了多达70%。检测量的下降与HbA1c异常结果的增加有关。